Your browser doesn't support javascript.
Antibody binding and ACE2 binding inhibition is significantly reduced for both the BA1 and BA2 omicron variants.
Junker, Daniel; Becker, Matthias; Wagner, Teresa R; Kaiser, Philipp D; Maier, Sandra; Grimm, Tanja M; Griesbaum, Johanna; Marsall, Patrick; Gruber, Jens; Traenkle, Bjoern; Heinzel, Constanze; Pinilla, Yudi T; Held, Jana; Fendel, Rolf; Kreidenweiss, Andrea; Nelde, Annika; Maringer, Yacine; Schroeder, Sarah; Walz, Juliane S; Althaus, Karina; Uzun, Gunalp; Mikus, Marco; Bakchoul, Tamam; Schenke-Layland, Katja; Bunk, Stefanie; Haeberle, Helene; Göpel, Siri; Bitzer, Michael; Renk, Hanna; Remppis, Jonathan; Engel, Corinna; Franz, Axel R; Harries, Manuela; Kessel, Barbora; Lange, Berit; Strengert, Monika; Krause, Gerard; Zeck, Anne; Rothbauer, Ulrich; Dulovic, Alex; Schneiderhan-Marra, Nicole.
  • Junker D; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Becker M; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Wagner TR; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Kaiser PD; Pharmaceutical Biotechnology, University of Tuebingen, Tuebingen, Germany.
  • Maier S; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Grimm TM; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Griesbaum J; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Marsall P; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Gruber J; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Traenkle B; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Heinzel C; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Pinilla YT; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Held J; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Fendel R; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Kreidenweiss A; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Nelde A; German Center for Infection Research (DZIF), Partner Site Tuebingen, Tuebingen, Germany.
  • Maringer Y; Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon.
  • Schroeder S; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Walz JS; German Center for Infection Research (DZIF), Partner Site Tuebingen, Tuebingen, Germany.
  • Althaus K; Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon.
  • Uzun G; Department of Peptide-based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.
  • Mikus M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Bakchoul T; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.
  • Schenke-Layland K; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
  • Bunk S; Department of Peptide-based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.
  • Haeberle H; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Göpel S; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.
  • Bitzer M; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
  • Renk H; Department of Peptide-based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.
  • Remppis J; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.
  • Engel C; Department of Otorhinolaryngology, Head and Neck Surgery, University of Tuebingen, Tuebingen, Germany.
  • Franz AR; Department of Peptide-based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.
  • Harries M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Kessel B; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.
  • Lange B; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
  • Strengert M; Center for Clinical Transfusion Medicine, Tuebingen, Germany.
  • Krause G; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Zeck A; Center for Clinical Transfusion Medicine, Tuebingen, Germany.
  • Rothbauer U; Center for Clinical Transfusion Medicine, Tuebingen, Germany.
  • Dulovic A; Center for Clinical Transfusion Medicine, Tuebingen, Germany.
  • Schneiderhan-Marra N; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Tuebingen, Germany.
Clin Infect Dis ; 2022 Jun 19.
Article in English | MEDLINE | ID: covidwho-2237813
ABSTRACT

BACKGROUND:

The rapid emergence of the omicron variant and its large number of mutations led to its classification as a variant of concern (VOC) by the WHO. Subsequently, omicron evolved into distinct sublineages (e.g. BA1 and BA2), which currently represent the majority of global infections. Initial studies of the neutralizing response towards BA1 in convalescent and vaccinated individuals showed a substantial reduction.

METHODS:

We assessed antibody (IgG) binding, ACE2 (Angiotensin-Converting Enzyme 2) binding inhibition, and IgG binding dynamics for the omicron BA1 and BA2 variants compared to a panel of VOC/VOIs, in a large cohort (n = 352) of convalescent, vaccinated, and infected and subsequently vaccinated individuals.

RESULTS:

While omicron was capable efficiently binding to ACE2, antibodies elicited by infection or immunization showed reduced binding capacities and ACE2 binding inhibition compared to WT. Whereas BA1 exhibited less IgG binding compared to BA2, BA2 showed reduced inhibition of ACE2 binding. Among vaccinated samples, antibody binding to omicron only improved after administration of a third dose.

CONCLUSION:

omicron BA1 and BA2 can still efficiently bind to ACE2, while vaccine/infection-derived antibodies can bind omicron. The extent of the mutations within both variants prevent a strong inhibitory binding response. As a result, both omicron variants are able to evade control by pre-existing antibodies.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid